About
Limited evidence suggests that when smoking history is controlled, this group is not at risk for COPD when compared with the general population9. For that reason, it is difficult to get accurate results regarding clinical phenotype. Although the S allele is more common than the Z allele, interestingly, PiSS is not as commonly found as other genotypes6,20,21. The association between PiSZ heterozygosity and risk of developing other complications of AATD such as panniculitis and granulomatosis with polyangiitis is controversial but smaller than PiZZ homozygosity7. It is possible that computed tomography (CT) densitometry or DLCO would be more informative regarding survival given that upper zone density decline is relevant to mortality11 and is common in PiSZ patients. Consequently, the S allele is only a minor risk factor or co-factor for cirrhosis in specific subpopulations such as chronic alcohol abusers.In the last decade, with the new taxonomy and etiopathogenesis of COPD, early-life risk factors, such as prematurity, low birth weight, and exposure to smoking (in intrauterine life and infancy), as well as asthma, infections, and environmental/occupational exposures throughout life, have been given ever greater weight.11,41 The influence of many of these risk factors for bronchopulmonary disease needs to be better studied in AATD, not only in relation to its early onset but also in relation to its progression. The prevalence was found to be 12.7% for the MS genotype, whereas it was 7.4%, 3.0%, 1.6%, and 0.8% for the MZ, ZZ, SZ, and SS genotypes, respectively.7 In another analysis of that sample of individuals,6 all variant alleles were evaluated and mutations were found in 9,528 (30.9%), of whom 818 (2.7%) had rare alleles (excluding all S and Z alleles). A review of the Spanish Registry of AATD patients from 1998 to 2010 revealed that 56 (1.6%) of 3,511 patients with AATD had rare alleles.27 In addition, higher serum concentrations of AAT are released, generally conferring protection of the lungs in nonsmokers.3 The alleles S, I, and Queen can also form polymers, although at a slower rate, facilitating their removal and rarely causing liver injury (Chart 1). The Z, SIiyama, MMalton, and King alleles do not affect synthesis, although 70% of the mutant AAT is retained within the hepatocyte and 15% forms polymers that are not fully degraded and accumulate in the liver, causing chronic disease.
BEAM-302 is a lipid nanoparticle-delivered base editing therapy designed to correct the PiZ mutation in the SERPINA1 gene, enabling production of normal AAT in liver cells. Clinical outcomes such as lung function or liver histology have not yet been reported. Your tax-deductible donation funds lung disease and lung cancer research, new treatments, lung health education, and more. If your healthcare provider suspects AAT deficiency is affecting the liver, the provider may order blood testing of liver function and in some cases an ultrasound of the liver. Lung and liver transplantation are reserved for severe and terminal cases of AATD.96 After liver transplantation, AATD is corrected because the phenotype-normal donor liver produces and secretes AAT. When AAT replacement is indicated, it should follow the criteria described in this document.1,9,108,114 Experience with lung volume reduction surgery in patients with AATD is limited. It is interesting to use questionnaires to assess quality of life, assess COPD, and monitor exacerbations.9,105 Despite the cost, AAT replacement is a specific treatment that will slow the destruction of the lung parenchyma, consequently increasing survival,108 and should therefore be offered to all those who need it.
If you’ve been diagnosed with Alpha-1, see your provider if you have any new symptoms or questions about your care, or if you’re having trouble managing your symptoms. Early diagnosis is important, so if you have COPD or asthma, ask your provider if you should get an Alpha-1 test. See your provider if you have symptoms of Alpha-1 or if a family member has Alpha-1. Follow your provider’s recommendations for other ways to stay healthy and manage your symptoms. This includes smoking, lung irritants, alcohol and certain medications. But that doesn’t mean you’ll develop the diseases it can cause. Some people live a normal life span and some have life-threatening complications.
If a diagnosis remains unclear, visiting a multidisciplinary care center or university hospital may help. Knowing if other family members have had the disease, also known as your family health history, can give your medical team important information. A biological parent can sometimes pass down genetic changes, called mutations, that cause a disease or increase the chances of developing it. Diagnostic techniques for AATD are improving, but milder genotypes (PiSZ and PiMZ) remain underdiagnosed in the general population. Only two studies have reported otherwise, with a 10-year survival superior in COPD patients then in AATD patients77,78. Anastomotic complications with dehiscence were seen only in AATD patients who were under AT and discontinued it before the transplant. Although these approaches are possible in selected patients, their long-term benefits remain to be elucidated.
The PiZZ genotype is the most common severe deficiency genotype and so tends to result in the worst clinical presentation, hence it has been the major focus of research. Clinical heterogeneity has been demonstrated in alpha-1 antitrypsin deficiency (AATD), such that clinical suspicion plays an important role in its diagnosis. The underlying pathophysiology for SHBG changes in liver disease remains subject to speculation. Elevated SHBG is well documented in a variety of other liver disorders such as alcoholic liver disease, haemochromatosis, while low SHBG is documented in non-alcoholic fatty liver disease.19